Autoimmune Modulation
77
síntese
3
2,400
advanced
May 17, 2026
Visão Geral
The Autoimmune Modulation stack represents an experimental approach to immune rebalancing for individuals with autoimmune conditions, focusing on reducing pathological inflammation while preserving immune competence. KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH''s potent anti-inflammatory properties while lacking its melanogenic (skin-darkening) effects. KPV inhibits NF-kB nuclear translocation — the master switch for inflammatory gene transcription — and reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. In animal models of inflammatory bowel disease, KPV demonstrated significant reduction in mucosal inflammation and disease activity. BPC-157 at the higher 500mcg oral dose targets the gastrointestinal tract directly, where many autoimmune conditions have their origins or maintenance mechanisms. The gut-associated lymphoid tissue (GALT) is the largest immune organ, and intestinal permeability ("leaky gut") is now recognized as a contributing factor in multiple autoimmune diseases including celiac disease, rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease. BPC-157''s ability to restore mucosal integrity and modulate local immune responses addresses this fundamental mechanism. Thymosin Alpha-1 is included not for immune stimulation per se, but for immune modulation — it helps restore the regulatory T-cell (Treg) populations that are often depleted in autoimmune conditions. Tregs are the "brakes" of the immune system, preventing overactivation and self-directed attacks. Ta1 promotes thymic output of naive T-cells that can differentiate into Tregs under appropriate conditions. The advanced classification reflects the complexity of autoimmune conditions and the absolute necessity of physician supervision. This stack should complement, never replace, prescribed immunomodulatory therapy. It is most appropriate for individuals in remission seeking to support ongoing immune balance.
Protocolo de Dose
200 mcg
por dose
500 mcg
por dose
1,500 mcg
por dose
Objetivos & Evidências
Avisos
- KPV (alpha-MSH fragment) has limited human data but promising anti-inflammatory research. This is an experimental immunomodulatory protocol. Do NOT replace prescribed immunosuppressants.
Comments
Sign in to join the discussion
Aviso: Esta pilha é submetida pela comunidade e para fins de pesquisa apenas. Peptide Contacts não verifica a segurança ou eficácia das pilhas submetidas. Sempre consulte um profissional de saúde qualificado antes de usar qualquer protocolo com peptídeos.